**
In a recent revelation, internal records have unveiled that top officials from the US Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, to deliberate on legal strategies, including potential Supreme Court actions concerning the controversial glyphosate herbicide. This meeting, held on 17 June 2025, raises significant questions about the interplay between corporate interests and public health, particularly as Bayer grapples with extensive litigation alleging that its glyphosate-based products, such as Roundup, contribute to cancer.
High-Stakes Meeting
The gathering involved not just Anderson, but also other prominent figures from Bayer, alongside key EPA officials, including Lee Zeldin, the agency’s administrator. The discussions were aimed at addressing ongoing litigation that has embroiled Bayer in legal battles with thousands of claimants asserting they developed cancer as a consequence of using the company’s herbicides. Central to these lawsuits is the assertion that Bayer did not adequately inform consumers about the potential cancer risks associated with glyphosate products.
Bayer has indicated that a critical component of its legal strategy is to persuade the Supreme Court that if the EPA does not mandate a cancer warning for glyphosate, Bayer should not be held accountable for not providing one. Although an appellate court has sided with Bayer on this preemption argument, various other jurisdictions have rejected it, complicating the company’s legal landscape.
Political Support and Implications
Following the June meeting, the Trump administration exhibited a series of actions that seemingly bolster Bayer’s position. For instance, a filing by Solicitor General D. John Sauer, appointed by the Trump administration, urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, scheduling a hearing for 27 April 2026. Additionally, the administration invoked the Defense Production Act to safeguard glyphosate production and shield its manufacturers, including Bayer, from potential liabilities.
Bayer has characterised the meeting as standard practice within the regulatory framework, asserting transparency in its dealings. However, critics argue this meeting illustrates a troubling trend of corporate influence over regulatory decisions. Nathan Donley from the Center for Biological Diversity, which obtained the records through a Freedom of Information Act request, expressed concern that the meeting underscores a prioritisation of corporate profits over public health.
Response from Environmental Advocates
Environmental advocates have voiced their discontent regarding the apparent prioritisation of corporate interests in regulatory discussions. Whitney Di Bona, a consumer safety advocate, highlighted the disturbing nature of a major pesticide company’s CEO having direct access to the EPA to discuss limiting liability while the voices of those affected by glyphosate remain unheard. This sentiment echoes across various advocacy groups, including Moms Across America, whose founder, Zen Honeycutt, remarked on the longstanding pattern of chemical companies exerting pressure on regulatory agencies.
Brigit Hirsh, the EPA press secretary, attempted to downplay the significance of the meeting, categorising it as routine and insisting that it did not specifically address ongoing litigation. Nonetheless, the planning email for the meeting indicated that legal issues, including potential Supreme Court actions, were to be key discussion points.
A Broader Trend
The implications of this high-level dialogue extend beyond Bayer and glyphosate. It reflects a broader concern regarding the extent of corporate influence in US regulatory processes. Naomi Oreskes, a Harvard professor and expert on corporate regulation, observed that such dynamics often favour industry leaders while sidelining the concerns of the general public. This pattern raises essential questions about the integrity of regulatory frameworks and the prioritisation of public health over corporate interests.
Why it Matters
The revelations surrounding the meeting between Bayer executives and high-ranking EPA officials illuminate a crucial intersection of corporate influence and public health policy. As legal battles over glyphosate continue and the regulatory landscape evolves, the implications for consumer safety and corporate accountability are profound. The ongoing scrutiny of such meetings is essential for ensuring that regulatory practices prioritise the health and well-being of the public rather than succumbing to corporate pressures. The future of pesticide regulation, consumer safety, and corporate accountability hangs in the balance, demanding vigilant oversight and transparency from both governmental and corporate entities.
